← All Hcw Biologics INC filings

Hcw Biologics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HCWB
Hcw Biologics INC
10-K: HCW Biologics Faces Going Concern Doubt Amid Losses
HCW Biologics Inc. reported significant losses and a material weakness in internal controls, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.
NASDAQ
HCWB
Hcw Biologics INC
10-K: HCW Biologics Reports Progress in Immunotherapy Development and Outlines Future Strategy in 10-K Filing
HCW Biologics' 10-K filing highlights advancements in its immunotherapy pipeline, strategic collaborations, and a shift towards its TRBC drug development platform for treating age-related diseases and cancer.
NASDAQ
HCWB
Hcw Biologics INC
10-K/A: HCW Biologics Restates 2023 Financials, Cites Criminal Scheme and Going Concern Doubts
HCW Biologics restated its 2023 financials due to a criminal scheme that misdirected funds and raised substantial doubt about the company's ability to continue as a going concern.
NASDAQ
HCWB
Hcw Biologics INC
10-K: HCW Biologics Inc. 10-K Filing: Immunotherapy Pipeline Advances Amidst Financial Challenges
HCW Biologics' 10-K filing details progress in its immunotherapy pipeline, including clinical trial updates for HCW9218 and plans for HCW9302, while also highlighting financial losses and the need for additional funding.